Promising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results

Brandon Folkes, an analyst from H.C. Wainwright, has initiated a new Buy rating on Eupraxia Pharmaceuticals (EPRX).

Brandon Folkes has given his Buy rating due to a combination of factors that highlight the promising potential of Eupraxia Pharmaceuticals’ lead product, EP-104GI. The treatment is positioned as a potentially best-in-class solution for eosinophilic esophagitis (EoE), a condition with limited current treatment options. Eupraxia’s proprietary delivery platform, DiffuSphere, enhances the targeted delivery and extended duration of the drug’s effect, which has shown promising efficacy in clinical trials.
The ongoing RESOLVE trial has demonstrated strong results, particularly in Cohort 5, where the drug continued to release effectively in the esophagus nine months post-administration, leading to sustained or improved patient outcomes. The trial data indicates significant clinical improvements and histologic markers, with a favorable safety profile. These positive results, combined with the potential for an annual dosing regimen, support the Buy rating and suggest a promising future for Eupraxia Pharmaceuticals in addressing the growing EoE market.

In another report released on June 16, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a C$9.00 price target.